PrimeRFP SCOUT · Federal Contract Recompete Brief

36C26322N0374Fy22 delivery ORDER for simplexa TESTS — Diasorin Molecular LLC

Diasorin Molecular LLC holds $16.5M across 436 federal awards. This PIID sits alongside 3 related awards under parent 36C26322D0009. PoP ended Sep 30, 2022 — the usual 12–18 month planning window is closed; recompete action looks late or overdue.

Network Contract Office 23 (36C263)

Awarding office

Diasorin Molecular LLC

Recipient

Sep 30, 2022

PoP end

$124K

Obligated

$148K

Potential

334516

NAICS

6640

PSC

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Diasorin Molecular LLC — $90

Contract facts

Federal

Contract number36C26322N0374

Also listed as36C263-22-N-0374

Also listed as36C26322D0009-36C26322N0374

AgencyNetwork Contract Office 23 (36C263)

Awarding officeNetwork Contract Office 23 (36C263)

Awarding agencyDepartment of Veterans Affairs (VA)

Funding agencyDepartment of Veterans Affairs (VA)

IncumbentDiasorin Molecular LLC

CAGE7V7H8

UEIKFFNMC55GHS5

NAICS334516

No full NAICS 334516 intel page yet. Browse NAICS intelligence

PSC6640

Parent IDIQ / IDV36C26322D0009

Place of performanceCYPRESS CA

Pricing typeFirm Fixed Price

Extent competedCompeted Under SAP

PoP startJan 20, 2022

PoP end (current)Sep 30, 2022

Obligated$124K

Current value$148K

Potential value$148K

FY22 DELIVERY ORDER FOR SIMPLEXA TESTS FOR MPLS VAHCS is a federal award for Network Contract Office 23 (36C263) held by Diasorin Molecular LLC. Estimated value $148K ($124K obligated). Current period of performance ends Sep 30, 2022. Place of performance: CYPRESS CA.

FY22 DELIVERY ORDER FOR SIMPLEXA TESTS FOR MPLS VAHCS

Recompete timing

Public

● Past PoP end (1421 days ago)

Current PoP ended Sep 30, 2022 (1421 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.

Incumbent footprint

Public record

Diasorin Molecular LLC — $16.5M obligated across 436 awards (firm-wide, all agencies).

Sole agency: Department of Defense (DOD)

Department of Defense (DOD)$249K · 100% of firm total

Open full company profile →

Related awards

Same parent · incumbent

36C25022P0732

SIMPLEXA COVID-19 TESTING SUPPLIES

$552K

Oct 31, 2026

36C24126N0536

HERPES VIROLOGY AND HISTOLOGY TESTING REAGENTS AND SUPPLIES

$150K

Apr 30, 2027

W81K0022P0269

PURSUANT TO FEDERAL ACQUISITION REGULATION (FAR) 52.217-9, OPTION TO EXTEND THE TERM OF TH…

$140K

Sep 30, 2027

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →

Frequently asked questions

What is contract 36C26322N0374?

36C26322N0374 (Fy22 delivery ORDER for simplexa TESTS) is a Network Contract Office 23 (36C263) award with a potential value of $148K, currently held by Diasorin Molecular LLC. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

What is 36C263-22-N-0374?

36C263-22-N-0374 is the dashed form of PIID 36C26322N0374 (Fy22 delivery ORDER for simplexa TESTS), held by Diasorin Molecular LLC. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.

Which office awarded 36C26322N0374?

Network Contract Office 23 (36C263) awarded 36C26322N0374 to Diasorin Molecular LLC (potential $148K).

Who is the incumbent on 36C26322N0374?

Diasorin Molecular LLC is the incumbent with $16.5M across 436 related awards in SCOUT’s public footprint. The current period of performance ends Sep 30, 2022.

When does Diasorin Molecular LLC’s 36C26322N0374 come up for recompete?

SCOUT tracks a period-of-performance end of Sep 30, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of Jun 25, 2026 · refreshed monthlyLatest procurement action Dec 14, 2022